Searchable abstracts of presentations at key conferences in endocrinology

ea0098c1 | Clinical – Chemo/SSA/Biologics | NANETS2023

Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients living with metastatic neuroendocrine tumors

Krishnan Tharani , Safro Maria , Moreira Furlanetto Daniel , Gill Sharlene , Paulo Solar Vasconcelos Joao , Stuart Heather C. , Martineau Patrick , Loree Jonathan M.

Background: Octreotide LAR is a long-acting somatostatin analogue used in the management of metastatic neuroendocrine tumors (NETs), with antiproliferative and symptom control effects. It requires intramuscular (IM) injection. Missed IM injections can cause subcutaneous nodules (SCNs) on radiologic images. We reviewed the rates of SCNs in a real-world cohort of NETs receiving octreotide LAR and explored treatment outcomes.Methods: Patients with gastroint...

ea0098c34 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

Comparative assessment of 111in-octreotide scintigraphy, 68GA-DOTATOC PET/CT and 18F-FDG PET/CT in the staging and management of neuroendocrine tumors (NETs)

Zaidi Ali , Chia Brendan , Zhou Marilyn , Ladua Gale , Ravi Pavithraa , Bloise Ingrid , Harsini Sara , Wilson Don , Benard Francois , Martineau Patrick , Loree Jonathan M

Background: Accurate imaging is essential for NETs. 111In-octreotide scintigraphy, 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT are the most commonly used modalities. This study compared the three modalities to ascertain the added value of newer functional imaging approaches.Methods: A retrospective review was performed on patients who underwent 68Ga-DOTATOC PET/CT and 18F-FDG PET/CT between 07/2018 and 03/2023 as part of a clinical trial at BC Cancer. Patient...